Skip to main content

Trial closure: two IND241 sub-studies

Trial closure: two IND241 sub studies

There have been permanent closures of two IND241 sub-studies:

  • IND241 B: A Phase II Study of RP-6306 in Patients with CDK4/6-Inhibitor Treated ER+HER2- Metastatic Breast Cancer Receiving Gemcitabine
  • IND241 D: A Phase II Study of Lunresertib Plus Camonsertib in Patients With CDK4/6 Inhibitor Treated ER+/HER2- Metastatic Breast Cancer
The main IND241 platform trial and all other associated sub-studies remain active, all other trial-related activities are unaffected. This closure is of the specified sub-studies ONLY.
 

This platform study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study.

Find out more on clincialtrials.gov NCT05601440.